Drug Profile
Rucaparib companion diagnostic - Clovis Oncology/Myriad Genetics
Alternative Names: BRACAnalysis CDx™ (Rucaparib); BRACAnalysis® (Rucaparib)Latest Information Update: 21 Sep 2023
Price :
$50
*
At a glance
- Originator Myriad Genetics
- Developer Clovis Oncology; Myriad Genetics
- Class Antineoplastics; Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ovarian cancer
Most Recent Events
- 21 Sep 2023 Discontinued - Clinical-Phase-Unknown for Ovarian cancer (Diagnosis) in USA (unspecified route)
- 28 May 2020 No recent reports of development identified for clinical-Phase-Unknown development in Ovarian-cancer(Diagnosis) in USA
- 27 Apr 2017 Clinical trials in Ovarian cancer in USA (unspecified route)